Kidney transplantation

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, JDRF, Kidney disease, Massachusetts General Hospital, Risk, Immunosuppression, Patient, Kidney transplantation, OLE, University, Tacrolimus, Glomerular filtration rate, Net, Investment, Society, Hospital, EGFR, Kidney, Safety, Pharmacokinetics, FACS, Annual general meeting, Pharmaceutical industry

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2023 operating and financial results and reviewed recent business highlights.

Key Points: 
  • In addition to our clinical development progress, tegoprubart was used for immunosuppression in historical kidney and heart pig-to-human xenotransplant procedures.
  • The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man with end-stage kidney disease.
  • Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting held in Philadelphia, PA in November 2023.
  • General and administrative expenses were $12.7 million for the year ended December 31, 2023, compared to $12.7 million for the year ended December 31, 2022.

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
ODD, Research, Hyperphosphatemia, DGF, CRRT, ERA, Administration, Congress, Conference, OLC, CKD, Patient, AKI, National Kidney Foundation, Mitochondrion, NDA, Kidney transplantation, Insurance, Kidney disease, Critical care, Acute kidney injury, Clinical trial, Therapy, Drug development, Safety, Chronic kidney disease, Dialysis, LOS, Research and development, SAD, FDA, KATP, Food, Pharmaceutical industry

LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.
  • Completed a private placement with new and existing healthcare institutional investors that generated $50 million in gross proceeds to Unicycive.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled $9.7 million.
  • Subsequent to year end, in March 2024, Unicycive completed a private placement of preferred stock which generated $50 million in gross proceeds.

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Retrieved on: 
Monday, March 25, 2024
Toxicity, Nephrotoxicity, Transplant, Organ transplantation, Central nervous system, Risk, Patient, Kidney transplantation, Tacrolimus, Thumbay Hospital, Life, Kidney, Immune system, Tremor, Hypertension, Immunosuppressive drug

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.

Key Points: 
  • IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
  • In transplantation procedures, organ rejection is a major cause of graft failure, which can be a life-threatening condition.
  • Rejection occurs due to allorecognition, wherein the recipient's immune system identifies the transplanted organ as foreign tissue, triggering an immune response against the transplanted organ.
  • Calcineurin inhibitors (“CNIs”) are a critical component of most immunosuppressive regimens to prevent acute and long-term organ transplant rejection.

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Retrieved on: 
Thursday, March 21, 2024
Organ transplantation, Kidney disease, University of Minnesota, Massachusetts General Hospital, Risk, Patient, Immunosuppression, Research, Kidney transplantation, University, Kidney, Hope, Tacrolimus, Doctor of Philosophy, MD, Person, Hospital, Heart, Immune system, Calcineurin, Division, CD40L, Dentistry

IRVINE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human. The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man living with end-stage kidney disease.

Key Points: 
  • The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man living with end-stage kidney disease.
  • “Eledon has now participated in both heart and kidney xenotransplant procedures, further demonstrating tegoprubart’s broad potential in transplant.
  • Tegoprubart has been observed to be safe and well-tolerated in multiple studies and in multiple indications, including for the prevention of rejection following kidney transplantation.
  • In parallel, Eledon is running two global clinical studies evaluating tegoprubart for the prevention of organ rejection in persons receiving a de novo kidney transplant.

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

Retrieved on: 
Wednesday, March 13, 2024
CRRT, DGF, Conference, AKI, Patient, Kidney transplantation, MD, Kidney disease, Critical care, Acute kidney injury, Therapy, Safety, Kidney, LOS, SAD, FDA, Administration, Pharmaceutical industry

LOS ALTOS, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two presentations related to UNI-494 were presented on March 12, 2024 at the 29th International Conference on Advances in Critical Care Nephrology AKI and CRRT 2024.

Key Points: 
  • “We are excited about the tremendous progress we have made with our second clinical development asset, UNI-494,” said, Shalabh Gupta, MD, Chief Executive Officer of Unicycive.
  • The oral presentation, entitled, “Intravenous Administration of UNI-494 Ameliorates Acute Kidney Injury in Rat Model of Delayed Graft Function” was delivered by Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive Therapeutics.
  • The study concluded that UNI-494 is a potential candidate for prevention of DGF and other AKI clinical conditions.
  • The poster, entitled, “UNI-494 Phase 1 Safety, Tolerability and Pharmacokinetics: Trial in Progress” was presented by Guru Reddy, PH.D., Vice President of Preclinical R&D, Unicycive Therapeutics.

Renowned Transplant Surgeon and Medical Innovator, Dr. Robert Mendez, Remembered for Lifelong Dedication to Advancing Organ Donation and Transplantation

Retrieved on: 
Tuesday, April 2, 2024
Science, Research, Surgery, General Health, Health, Hospitals, Philanthropy, Foundation, UNOS, Foreign policy, Organ transplantation, Surgeon, Sharp HealthCare, Transplant, Education, Keck Hospital of USC, Knowledge, University, Kidney transplantation, General surgery, Death, MD, Parliament, Overmyer Network, St. Vincent's Hospital, Stanford University, Bangladesh Technical Education Board, Multimedia, Family, MNIT, Flower, Medicine, Dentistry

Along with his twin brother, Dr. Rafael Mendez, Dr. Robert Mendez was a worldwide pioneer in kidney transplantation and organ donation, who revolutionized the field with his expertise and dedication.

Key Points: 
  • Along with his twin brother, Dr. Rafael Mendez, Dr. Robert Mendez was a worldwide pioneer in kidney transplantation and organ donation, who revolutionized the field with his expertise and dedication.
  • View the full release here: https://www.businesswire.com/news/home/20240401597673/en/
    From Left to Right: Dr. Rafael Mendez and Dr. Robert Mendez, organ donation and transplantation pioneers.
  • (Photo: Business Wire)
    Born on March 2, 1937, Dr. Robert Mendez embarked on a remarkable career that spanned over four decades.
  • Dr. Robert Mendez’s impact on the world of organ transplantation, organ donation and medicine at large are immeasurable.

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
Thursday, March 21, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Death, Autosome, VRTX, Growth, Disease, PC1, Patient, Kidney failure, Kidney transplantation, Polycystic kidney disease, IND, Vertex Pharmaceuticals, PKD1, Vertex, ADPKD, Dialysis, Cystic fibrosis, Food, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.
  • ADPKD is the most common inherited kidney disease, with an estimated 250,000 people in the U.S. and Europe living with ADPKD; however, there are no treatments currently available that address the underlying causal biology of the disease.
  • ADPKD is a life-shortening genetic kidney disease characterized by the growth of numerous kidney-enlarging cysts that impair kidney function and can ultimately lead to kidney failure, requiring dialysis or kidney transplantation, and premature death.
  • The majority of ADPKD cases are caused by variants in the PKD1 gene, which encodes the polycystin 1 (PC1) protein.

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

Retrieved on: 
Thursday, March 21, 2024
Research, Other Health, General Health, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Pelvic floor dysfunction, MGH, Kidney disease, Gene, Organization, Survival, Massachusetts General Hospital, Transplant, Inflammation, Immunosuppression, Kidney failure, Mortality, Coagulation, Hope, Doctor of Philosophy, Expanded access, Quality of life, Genome, Transgene, Hospital, Kidney, Dialysis, CD40L, Courage, Kidney transplantation, Medicine, Dentistry

eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.
  • Following the procedure, the patient is in good condition and recovering well at MGH.
  • Yet the demand for organs far outpaces supply, with more than 90,000 individuals on the kidney waitlist and approximately 25,000 kidney transplants performed each year.
  • Decades of progress in cross-species transplantation, accelerated by the advancement of modern genome editing tools and next-generation sequencing, have enabled eGenesis to progress genetically engineered organs to the clinical setting.

Hansa Biopharma publishes 2023 Annual and Sustainability Reports

Retrieved on: 
Thursday, March 21, 2024
Certification, Culture, Crigler–Najjar syndrome, Science, Partnership, Patient, Neutron, Hansa, Duchenne muscular dystrophy, Kidney transplantation, Commercial, Syndrome, GBS, Clinical trial, Therapy, Drug development, Sarepta Therapeutics, Safety, Pharmacokinetics, ANCA, DMD, Pharmaceutical industry

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a default sustainable organization.

Key Points: 
  • LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports.
  • Peter Nicklin, Chairman of the Board, Hansa Biopharma, said: "2023 was another important year for Hansa Biopharma.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "In 2023, the Company's focus remained firmly on advancing cutting-edge science and delivering new treatments in areas of high unmet need.
  • This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

Hansa Biopharma publishes 2023 Annual and Sustainability Reports

Retrieved on: 
Thursday, March 21, 2024
Certification, Culture, Crigler–Najjar syndrome, Science, Partnership, Patient, Neutron, Hansa, Duchenne muscular dystrophy, Kidney transplantation, Commercial, Syndrome, GBS, Clinical trial, Therapy, Drug development, Sarepta Therapeutics, Safety, Pharmacokinetics, ANCA, DMD, Pharmaceutical industry

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a default sustainable organization.

Key Points: 
  • LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports.
  • Peter Nicklin, Chairman of the Board, Hansa Biopharma, said: "2023 was another important year for Hansa Biopharma.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "In 2023, the Company's focus remained firmly on advancing cutting-edge science and delivering new treatments in areas of high unmet need.
  • This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.